SESSION 1: THE CHALLENGES
- Lothar Bergmann (Frankfurt University Hospital) – Keynote Lecture: Impact of Drug Access on Survival
- Matteo Scarabelli (EURORDIS) – How to Involve Patients in HTA
- Steen Werner Hansen (Herlev Hospital) – A Clinician’s Point of View on How to Provide Best Therapy to their Cancer Patients
- Alexander Roediger (Chair EFPIA Oncology Steering Group / MSD) – The Cancer Challenge: a Multi-Faceted Challenge
SESSION 2: CURRENT LANDSCAPE
- Iñaki Imaz-Iglesia (EUnetHTA) – Differences of HTA in Europe
- Afschin Gandjour (Frankfurt School of Finance & Management) – Implications of Value-Based Pricing
- Lidija Kandolf Sekulovic (Military Medical Academy University of Belgrade) – Access to New Drugs for Metastatic Melanoma in Euorpe and the Role of ESMO Magnitude of Benefit Scale
- Elisa Sulleiro (AEMPS) – Regulation / HTA: How to Define Common Grounds?
- Florian Jantschak (G-BA, Federal Joint Committee) – Pricing and Reimbursement Decisions in Germany
- Report on Drug Reimbursement
SESSION 3: THE WAY AHEAD
- Ivana Cattaneo (Vice-Chair EFPIA Oncology Steering Group / Novartis) – How to Create an Overall Win Situation?
- Eveline Scheres (Dutch Cancer Foundation) – How to Meet the Challenges of Affordability of Novel Anti-Cancer Drugs?
- Todd Riehl (Genentech) – Industry Perspective
- Marc Van de Casteele (RIZIV/INAMI) – Approaches for Payer’s Decision
SESSION 4: TIME FOR A EUROPEAN HTA EVALUATION?
- Davide Integlia (Innovation area I-Com, Institute for competitiveness) – EU Initiatives on HTA
- Sonia García Pérez (AEMPS) – The EunetHTA Experience: Lessons learnt for a New EU HTA Cooperation
- Dan Cimpoeru (ECPC) – What Cancer Patients Need from a European HTA
- Deborah Maskens (International Kidney Cancer Coalition) – Cancer Patients’ Role in HTA